盐酸凯普拉生片治疗反流性食管炎的成本-效果
Cost-effectiveness of Kenuolazan Hydrochloride Tablets in the Treatment of Refluxc Esophagitis
程莉丽 1陈卓 2李自刚 2陈鑫 2曹珲3
作者信息
- 1. 江苏省医药行业协会,南京 210015
- 2. 复星医药(国内营销平台),上海 200233
- 3. 江苏柯菲平医药股份有限公司,南京 210015
- 折叠
摘要
目的 评价盐酸凯普拉生片用于反流性食管炎(RE)患者治疗的经济性.方法 以RE患者为研究对象,基于医保支付方角度,构建Markov模型模拟患者单次病程的健康效用和直接医疗费用,并使用成本-效果分析法比较凯普拉生方案和伏诺拉生方案的增量成本-效果比,从而评价盐酸凯普拉生片的经济优势,并进行敏感性分析来验证结果的稳定性.结果 凯普拉生治疗方案的总成本为2 225.40 元,总质量调整生命年(QALYs)为1.082 81;伏诺拉生治疗方案的总成本为2 340.78元,总QALYs为1.082 40;凯普拉生方案相比伏诺拉生治疗方案增量成本-效果比(ICER)为-280 500.50元/QALY.敏感性分析中各因素对研究结论无明显影响.结论 在对 RE 患者的治疗中,凯普拉生治疗方案与伏诺拉生治疗方案相比具有绝对优势.
Abstract
Objective To evaluate the effectiveness and economy of kenuolazan hydrochloride tablets in the treatment of patients with reflux esophagitis(RE).Methods Using RE patients as the research subjects,from the perspective of medical insurance payer,we construct a Markov model to simulate the health utility and direct medical costs under each reference regimen,evaluating the economy of kenuolazan regimen compared to vonoprazan regimen in the treatment of reflux esophagitis based on the Incremental Cost-effectiveness Ratio(ICER),and sensitivity analysis was performed to verify the stability of the results.Results The total cost of the kenuolazan regimen was RMB 2 225.40 with total QALYs of 1.082 81,and the total cost of the vonoprazan regimen was RMB 2 340.78 with total QALYs of 1.082 40.The ICER was-280 500.50 RMB/QALY.The factors in the sensitivity analysis had no significant impact on the study findings.Conclusion In the treatment of RE patients,the kenuolazan regimen has a clear advantage over the vonoprazan regimen.
关键词
盐酸凯普拉生片/富马酸伏诺拉生片/反流性食管炎/成本-效果Key words
Kenuolazan hydrochloride/Vonoprazan fumarate/Reflux esophagitis/Cost-effectiveness引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据